{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:49:37Z","timestamp":1793371777496,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008054","name":"Ramon Areces Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.vaccine.2025.127671","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:42:55Z","timestamp":1758577375000},"page":"127671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Assessment of critical bioprocess parameters for broadly cross-reactive chimeric hemagglutinin influenza virus vaccines"],"prefix":"10.1016","volume":"64","author":[{"given":"Michael J.","family":"Scherm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"H\u00f6lzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gonz\u00e1lez-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hjorth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean S.","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen F.","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Martik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Puente-Massaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127671_bb0005","volume":"2024","author":"Preliminary Flu Vaccine Effectiveness (VE) Data for 2023","year":"2024"},{"key":"10.1016\/j.vaccine.2025.127671_bb0010","article-title":"Advances in the development of influenza virus vaccines","volume":"167-182","author":"Krammer","year":"2015","journal-title":"Nat Rev. Drug Discovery Nat. Publishing"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127671_bb0015","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1128\/JVI.00137-12","article-title":"Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes","volume":"86","author":"Hai","year":"2012","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127671_bb0020","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1128\/JVI.03060-15","article-title":"Influenza a viruses expressing intra- or intergroup chimeric hemagglutinins","volume":"90","author":"Chen","year":"2016","journal-title":"J Virol"},{"issue":"37","key":"10.1016\/j.vaccine.2025.127671_bb0025","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi4753","article-title":"Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice","volume":"9","author":"Puente-Massaguer","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2025.127671_bib131","doi-asserted-by":"crossref","first-page":"127388","DOI":"10.1016\/j.vaccine.2025.127388","article-title":"Combination of recombinant neuraminidase with cHA-based inactivated split vaccines improves the breadth of cross-reactivity and protection against influenza viruses in mice","volume":"61","author":"Puente-Massaguer","year":"2025","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127671_bb0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","article-title":"A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial","volume":"27","author":"Nachbagauer","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127671_bb0035","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(22)00024-X","article-title":"Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial","volume":"22","author":"Folschweiller","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127671_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1097349","article-title":"Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses","volume":"11","author":"Puente-Massaguer","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"issue":"45","key":"10.1016\/j.vaccine.2025.127671_bb0045","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1016\/j.vaccine.2016.07.046","article-title":"Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers","volume":"34","author":"Wahid","year":"2016","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2025.127671_bb0050","doi-asserted-by":"crossref","first-page":"10580","DOI":"10.1128\/JVI.01213-08","article-title":"Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach","volume":"82","author":"Hai","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2025.127671_bb0055","article-title":"Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system","volume":"81","author":"Margine","year":"2013","journal-title":"J Vis Exp"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127671_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194830","article-title":"An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations","volume":"13","author":"Rajendran","year":"2018","journal-title":"PloS One"},{"issue":"6464","key":"10.1016\/j.vaccine.2025.127671_bb0065","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1126\/science.aay0678","article-title":"Broadly protective human antibodies that target the active site of influenza virus neuraminidase","volume":"366","author":"Stadlbauer","year":"2019","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127671_bb0070","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.immuni.2023.07.004","article-title":"Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo","volume":"56","author":"Hansen","year":"2023","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127671_bb0075","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","article-title":"Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies","volume":"173","author":"Chen","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.127671_bb0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0021-9673(01)93874-9","article-title":"Comparison of protein a, protein G and copolymerized hydroxyapatite for the purification of human monoclonal antibodies","volume":"476","author":"Jungbauer","year":"1989","journal-title":"J Chromatogr"},{"issue":"44","key":"10.1016\/j.vaccine.2025.127671_bb0085","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1016\/j.vaccine.2015.09.029","article-title":"Improved stability of recombinant hemagglutinin using a formulation containing sodium thioglycolate","volume":"33","author":"Rhodes","year":"2015","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127671_bb0090","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41541-024-01014-8","article-title":"Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach","volume":"9","author":"Gonzalez-Dominguez","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127671_bb0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/bit.20599","article-title":"Tangential flow microfiltration and ultrafiltration for human influenza a virus concentration and purification","volume":"92","author":"Wickramasinghe","year":"2005","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.vaccine.2025.127671_bb0100","doi-asserted-by":"crossref","unstructured":"Kon, T.C., et al., Influenza vaccine manufacturing: Effect of inactivation, splitting and site of manufacturing comparison of influenza vaccine production processes, in PLOS ONE, F. Krammer, Editor. 2016. p. e0150700.","DOI":"10.1371\/journal.pone.0150700"},{"key":"10.1016\/j.vaccine.2025.127671_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.omtm.2020.08.013","article-title":"The effect of residual Triton X-100 on structural stability and infection activity of adenovirus particles","volume":"19","author":"Ma","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"22","key":"10.1016\/j.vaccine.2025.127671_bb0110","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.vaccine.2017.03.016","article-title":"A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography","volume":"36","author":"Tseng","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127671_bb0115","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s11095-015-1833-9","article-title":"Enhanced stability of inactivated influenza vaccine encapsulated in dissolving microneedle patches","volume":"33","author":"Chu","year":"2016","journal-title":"Pharm Res"},{"issue":"24","key":"10.1016\/j.vaccine.2025.127671_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126269","article-title":"A recombinant N2 neuraminidase-based CpG 1018(R) adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters","volume":"42","author":"Hoxie","year":"2024","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127671_bb0125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41541-022-00486-w","article-title":"A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice","volume":"7","author":"Strohmeier","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127671_bb0130","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02241-21","article-title":"A novel recombinant influenza virus neuraminidase vaccine candidate stabilized by a measles virus phosphoprotein Tetramerization domain provides robust protection from virus challenge in the mouse model","volume":"12","author":"Strohmeier","year":"2021","journal-title":"mBio"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:49:46Z","timestamp":1769024986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25009685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"alternative-id":["S0264410X25009685"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127671","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of critical bioprocess parameters for broadly cross-reactive chimeric hemagglutinin influenza virus vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"127671"}}